A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation
Latest Information Update: 21 Aug 2025
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms ORATOS
- Sponsors AstraZeneca
Most Recent Events
- 05 Aug 2025 Planned initiation date changed from 30 Sep 2025 to 14 Nov 2025.
- 30 Jul 2025 New trial record